(Q35771157)

English

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

scientific article published on May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Europe PubMed Central

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Constantine S. Tam

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Max M Wolf

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

E Henry Januszewicz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

H Miles Prince

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David Westerman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

John F Seymour

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

100

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

2181-2189

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15139062%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

21 January 2018

Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

21 January 2018

Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

21 January 2018

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20234

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35771157&oldid=1523605878"